AD Pipeline Watch: Corvus Pharmaceuticals’ ITK Inhibitor Shows Promise in Phase 1 AD Trial
Corvus Pharmaceuticals, Inc.’s Soquelitinib demonstrated a favorable safety profile and efficacy profile in patients with moderate to severe atopic dermatitis (AD), according to interim data from a Phase 1 clinical trial. Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit interleukin (IL)-2-inducible T cell kinase (ITK), an enzyme that […]